1. Home
  2. TEX vs CELC Comparison

TEX vs CELC Comparison

Compare TEX & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Terex Corporation

TEX

Terex Corporation

HOLD

Current Price

$54.87

Market Cap

3.0B

Sector

Industrials

ML Signal

HOLD

Logo Celcuity Inc.

CELC

Celcuity Inc.

HOLD

Current Price

$102.35

Market Cap

3.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TEX
CELC
Founded
1933
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Construction/Ag Equipment/Trucks
Medical Specialities
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.0B
3.1B
IPO Year
N/A
2017

Fundamental Metrics

Financial Performance
Metric
TEX
CELC
Price
$54.87
$102.35
Analyst Decision
Buy
Strong Buy
Analyst Count
10
8
Target Price
$57.50
$100.13
AVG Volume (30 Days)
1.2M
947.3K
Earning Date
02-05-2026
11-12-2025
Dividend Yield
1.24%
N/A
EPS Growth
N/A
N/A
EPS
2.34
N/A
Revenue
$5,344,000,000.00
N/A
Revenue This Year
$6.98
N/A
Revenue Next Year
$4.25
N/A
P/E Ratio
$23.33
N/A
Revenue Growth
4.60
N/A
52 Week Low
$31.53
$7.58
52 Week High
$58.66
$112.64

Technical Indicators

Market Signals
Indicator
TEX
CELC
Relative Strength Index (RSI) 67.74 60.99
Support Level $51.20 $97.27
Resistance Level $54.23 $105.14
Average True Range (ATR) 1.51 5.04
MACD 0.58 -1.29
Stochastic Oscillator 94.69 33.80

Price Performance

Historical Comparison
TEX
CELC

About TEX Terex Corporation

Terex is a global manufacturer of aerial work platforms, materials processing equipment, and specialty equipment for the waste, recycling, and utility industries. Its current composition is a result of numerous acquisitions over several decades to focus on a smaller group of light construction and other vocational equipment, having divested a handful of underperforming businesses, particularly in cranes and other lifting equipment. These remaining segments see heavy demand in nonresidential construction (aerial work platforms—40% sales), aggregates/mining (materials processing—30% sales), environmental, waste/recycling and utilities (environmental solutions group—30% sales).

About CELC Celcuity Inc.

Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.

Share on Social Networks: